On a new deal spree, Re­gen­eron buys in­to ISA in pur­suit of a check­point com­bo

Re­gen­eron and Sanofi $SNY aim to field the sixth new en­try in the PD-1/L1 space next year, and like their ri­vals they have some big plans for fol­lowup ap­provals in a rush to com­mand new mar­ket nich­es.

This morn­ing Re­gen­eron $REGN an­nounced that it will pur­sue a com­bi­na­tion pro­gram match­ing its check­point cemi­plimab with an HPV16-tar­get­ing drug from the Dutch biotech ISA for cer­vi­cal and head-and-neck can­cers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.